Anthralin therapy for alopecia areata.
Topical anthralin application producing a brisk irritant contact dermatitis has been reported to have therapeutic benefit in alopecia areata. A pilot clinical study was undertaken to determine whether topical anthralin application in doses low enough to produce only minimal contact dermatitis would produce a similar therapeutic response. None of the patients in the study received any benefit from this low-dose regimen. If anthralin is of benefit in the therapy of alopecia areata, a significant irritant contact dermatitis is apparently required.
D000287:Administration, Topical; D000506:Alopecia Areata / Q000188:drug therapy*; D000873:Anthracenes / Q000627:therapeutic use*; D000875:Anthralin / Q000008:administration & dosage / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D006801:Humans
D000873:Anthracenes; D000875:Anthralin